Farnaz Tabatabaian, MD, MS, associate professor, Division of Allergy & Immunology, Department of Internal Medicine, USF Health Morsani College of Medicine, provides background on mast cell biology and discusses mastocytosis presentation. Dr Tabatabaian also reviews current and emerging therapeutic options for patients.
Distinguishing indolent from advanced systemic mastocytosis is notoriously complex, even for seasoned clinicians. To simplify diagnosis, researchers developed a mathematical model using basic lab values, achieving 93% predictive…
In an interview conducted at the 2024 Congress of the European Hematology Association in Madrid, Spain, Lindsay Rein, MD, Duke University Medical Center, Durham, North Carolina, provided insights…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
John M. Fahrenholz, MD, Vanderbilt University Medical Center, Nashville, Tennessee, discusses questions about nonadvanced systemic mastocytosis submitted by participants. Topics include triggers for mast cell activation, management strategies…
Presented by the Florida Society of Clinical Oncology, this program provides opportunities for patients and caregivers to learn and share information regarding a diagnosis of systemic mastocytosis. Pankit…
